



BRITISH COLUMBIA  
CENTRE *for* EXCELLENCE  
*in* HIV/AIDS

# B.C. HIV/AIDS Drug Treatment Program

Monthly Report

February 2018





# HIV/AIDS Drug Treatment Program

## Monthly Report

© 2018 BC Centre for Excellence in HIV/AIDS

**DISCLAIMER:** This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

### **BC Centre for Excellence in HIV/AIDS Drug Treatment Program**

St. Paul's Hospital  
608 - 1081 Burrard Street  
Vancouver, BC  
V6Z 1Y6

Tel: 604.806.8202  
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677  
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222  
Website: [www.cfenet.ubc.ca](http://www.cfenet.ubc.ca)  
Email: [info@cfenet.ubc.ca](mailto:info@cfenet.ubc.ca)

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)



BRITISH COLUMBIA  
CENTRE for EXCELLENCE  
in HIV/AIDS



This document is best viewed in colour.  
Drug definitions available in the back.



## EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





## TABLE OF CONTENTS

### 1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

### 2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





## Table of Contents, cont'd...

### 3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

### 4. Health Authority Tables

#### INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

### 5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

February 2018

N = 7237



Health Authority	Male	Female	All
FRASER	1385	392	1777
INTERIOR	375	94	469
NORTHERN	141	78	219
VANCOUVER COASTAL	3404	454	3858
VANCOUVER ISLAND	724	151	875
	<b>6029</b>	<b>1169</b>	<b>7198</b>
		<b>Unknown/not stated:</b>	<b>39</b>
		<b>Total:</b>	<b>7237</b>

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






### 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (February 2013 - February 2018)






### 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (February 2013 - February 2018)






### 1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (February 2013 - February 2018)






### 1.5 BC-CfE Enrollment: New Antiretroviral Participants (February 2013 - February 2018)






1.6 Percent Distribution of Active Participants by CD4 Count  
(February 2013 - February 2018)






1.7 Percent Distribution of Inactive Participants by CD4 Count  
(February 2013 - February 2018)






### 1.8 Active and Inactive Participants (February 2013 - February 2018)






### 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (February 2013 - February 2018)






### 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (February 2013 - February 2018)






### 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(February 2013 - February 2018)






### 1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (February 2013 - February 2018)






### 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(February 2013 - February 2018)






### 1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (February 2013 - February 2018)






**1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT**

(February 2013 - February 2018)






### 1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (February 2013 - February 2018)






### 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(February 2013 - February 2018)






1.18 Baseline CD4 for Antiretroviral First Starts  
(February 2013 - February 2018)






**1.19 DTP Participants with PVL Measurement within previous five years, and never on ART  
(February 2013 - February 2018)**






### 1.20 Cumulative Resistance Testing Results by Resistance Category (February 2013 - February 2018)





### 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (February 2013 - February 2018)





## 2.1 Duration of ARV treatment in the Province of BC, 1987-2018 (for HIV+ persons currently on treatment)

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	26	4	0	4	4	870	4	<40	4
1988	27	7	0	7	7	590	7	<40	3
1989	25	56	2	58	47	500	54	<40	3
1990	24	61	1	62	60	530	62	<40	3
1991	24	37	3	40	34	520	40	<40	3
1992	23	68	5	73	57	530	68	<40	3
1993	23	141	15	156	145	580	155	<40	3
1994	21	86	14	100	84	605	96	<40	3
1995	21	129	21	150	126	600	144	<40	3
1996	19	360	53	413	357	610	398	<40	3
1997	17	293	36	329	284	650	299	<40	3
1998	17	206	43	249	219	590	240	<40	3
1999	16	174	40	214	187	570	206	<40	3
2000	17	127	35	162	137	570	152	<40	3
2001	16	128	31	159	135	530	151	<40	3
2002	15	135	30	165	142	565	156	<40	3
2003	14	163	29	192	166	590	183	<40	3
2004	13	168	39	207	173	608	199	<40	3
2005	12	189	46	235	203	610	229	<40	3
2006	11	198	45	243	197	590	226	<40	3
2007	10	268	47	315	266	600	294	<40	3
2008	9	307	70	377	311	620	355	<40	3
2009	9	332	70	402	333	630	376	<40	3
2010	8	291	71	362	304	635	339	<40	3
2011	7	347	73	420	357	680	390	<40	3
2012	6	280	67	347	296	700	329	<40	3
2013	5	275	66	341	278	679	317	<40	3
2014	4	299	55	354	290	720	331	<40	3
2015	3	299	50	349	289	680	332	<40	3
2016	2	306	64	370	317	656	356	<40	3
2017	1	260	41	301	271	590	296	<40	3
2018	0	50	8	58	56	555	57	328	3
<b>Total:</b>		<b>6044</b>	<b>1170</b>	<b>7214</b>					

**Definitions:**

**On treatment** defined as being on ARV therapy in the specified month and not reported deceased

**Duration** defined as cumulative years on ARV therapy, excluding periods of treatment interruption

**Current CD4 and PVL tests** defined as tests done in the last 6 months (most recent)

**Current ARV** defined as number of ARV drugs in the current regimen





## 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2017	7182	747	2326	<40	2073	590
FEB-2017	7134	755	1912	<40	1738	590
MAR-2017	7186	745	2203	<40	2017	600
APR-2017	7178	746	1966	<40	1766	590
MAY-2017	7224	744	2276	<40	2056	590
JUN-2017	7246	752	2119	<40	1951	596
JUL-2017	7242	753	1965	<40	1781	580
AUG-2017	7266	757	2105	<40	1879	590
SEP-2017	7223	762	2041	<40	1835	610
OCT-2017	7249	769	2191	<40	1918	610
NOV-2017	7246	766	2074	<40	1844	610
DEC-2017	7234	775	1742	<40	1506	610
JAN-2018	7290	757	2383	<40	2018	620
FEB-2018	7237	762	1894	<40	1615	620

**Definitions:**

**Active patient** defined as being on ARV treatment in the specified month

**Therapy days** defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

**PVL and CD4 tests** defined as tests done in the specified month





### 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2017	1540	2523	88	140	79	420
FEB-2017	1596	2300	80	1874	70	400
MAR-2017	1550	2482	100	568	90	380
APR-2017	1568	2454	94	545	84	420
MAY-2017	1542	2613	86	148	76	420
JUN-2017	1532	2672	76	197	68	485
JUL-2017	1554	2574	69	316	62	515
AUG-2017	1551	2611	78	160	68	495
SEP-2017	1608	2429	75	279	67	420
OCT-2017	1582	2570	88	200	76	470
NOV-2017	1601	2524	78	163	68	360
DEC-2017	1631	2331	59	61	48	380
JAN-2018	1593	2592	80	697	69	380
FEB-2018	1661	2244	93	70	74	455

**Definitions:**

**Inactive patient** defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

**Days off therapy** defined as number of days elapsed since last ARV treatment

**PVL and CD4 tests** defined as tests done in the specified month





**2.4 BC-CfE Enrollment**

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2017	7144	1540	21	21	141	144	-5	12876
FEB-2017	7104	1596	10	24	136	185	-40	12910
MAR-2017	7150	1550	17	19	189	140	46	12936
APR-2017	7141	1568	12	20	143	154	-9	12968
MAY-2017	7194	1542	7	22	170	128	53	13002
JUN-2017	7212	1532	10	24	151	137	18	13032
JUL-2017	7206	1554	7	14	134	144	-6	13051
AUG-2017	7230	1551	10	25	156	141	24	13081
SEP-2017	7187	1608	12	16	137	180	-43	13110
OCT-2017	7220	1582	7	7	185	150	33	13125
NOV-2017	7216	1601	16	20	139	146	-4	13160
DEC-2017	7213	1631	4	19	156	173	-3	13192
JAN-2018	7264	1593	11	10	191	135	51	13219
FEB-2018	7214	1661	8	24	124	189	-50	13253

**Definitions:**

**Currently on ARV Therapy** defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

**Currently off ARV Therapy** defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

**Deceased** defined as deceased in the specified month, and being on ARV treatment in the previous month

**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)

**Experienced Starts** defined as starting ARV treatment in the specified month, but previously being treated with ARVs

**New Inactive** defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

**Net Change** is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





**2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs**

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2017	61	6615	443	63	<b>7182</b>	0.85%	92.11%	6.17%	0.88%	<b>100.00%</b>
FEB-2017	60	6579	440	55	<b>7134</b>	0.84%	92.22%	6.17%	0.77%	<b>100.00%</b>
MAR-2017	60	6629	439	58	<b>7186</b>	0.83%	92.25%	6.11%	0.81%	<b>100.00%</b>
APR-2017	58	6633	428	59	<b>7178</b>	0.81%	92.41%	5.96%	0.82%	<b>100.00%</b>
MAY-2017	62	6665	438	59	<b>7224</b>	0.86%	92.26%	6.06%	0.82%	<b>100.00%</b>
JUN-2017	57	6691	439	59	<b>7246</b>	0.79%	92.34%	6.06%	0.81%	<b>100.00%</b>
JUL-2017	61	6685	434	62	<b>7242</b>	0.84%	92.31%	5.99%	0.86%	<b>100.00%</b>
AUG-2017	61	6696	448	61	<b>7266</b>	0.84%	92.16%	6.17%	0.84%	<b>100.00%</b>
SEP-2017	57	6678	431	57	<b>7223</b>	0.79%	92.45%	5.97%	0.79%	<b>100.00%</b>
OCT-2017	58	6696	438	57	<b>7249</b>	0.80%	92.37%	6.04%	0.79%	<b>100.00%</b>
NOV-2017	59	6687	444	56	<b>7246</b>	0.81%	92.29%	6.13%	0.77%	<b>100.00%</b>
DEC-2017	58	6673	447	56	<b>7234</b>	0.80%	92.24%	6.18%	0.77%	<b>100.00%</b>
JAN-2018	57	6728	450	55	<b>7290</b>	0.78%	92.29%	6.17%	0.75%	<b>100.00%</b>
FEB-2018	61	6669	449	58	<b>7237</b>	0.84%	92.15%	6.20%	0.80%	<b>100.00%</b>

**Definitions:**

**Number of Drugs** is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





**2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT**

	lamivudine		abacavir		zidovudine		stavudine		didanosine		tenofovir <TAF>		tenofovir <TDF>	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2017	13 41%	3068 44%	13 41%	2772 40%	0 0%	75 1%	0 0%	5 0%	0 0%	6 0%	0 0%	46 1%	19 59%	4050 58%
FEB-2017	12 35%	3074 44%	10 29%	2783 40%	1 3%	71 1%	0 0%	5 0%	0 0%	6 0%	0 0%	50 1%	22 65%	3981 58%
MAR-2017	7 27%	3105 45%	7 27%	2824 41%	0 0%	69 1%	0 0%	6 0%	0 0%	5 0%	0 0%	78 1%	19 73%	4000 57%
APR-2017	13 41%	3114 45%	12 38%	2834 41%	1 3%	68 1%	0 0%	6 0%	0 0%	6 0%	0 0%	96 1%	19 59%	3962 57%
MAY-2017	9 26%	3159 45%	9 26%	2881 41%	0 0%	73 1%	0 0%	6 0%	0 0%	5 0%	1 3%	119 2%	24 71%	3930 56%
JUN-2017	6 20%	3170 45%	6 20%	2903 41%	0 0%	71 1%	0 0%	6 0%	0 0%	5 0%	2 7%	143 2%	22 73%	3898 55%
JUL-2017	7 37%	3199 46%	7 37%	2929 42%	0 0%	72 1%	0 0%	6 0%	0 0%	5 0%	0 0%	161 2%	12 63%	3861 55%
AUG-2017	6 20%	3224 46%	4 13%	2958 42%	0 0%	69 1%	0 0%	6 0%	0 0%	5 0%	2 7%	171 2%	23 77%	3837 54%
SEP-2017	10 34%	3214 46%	10 34%	2951 42%	0 0%	66 1%	0 0%	5 0%	0 0%	4 0%	3 10%	207 3%	16 55%	3774 54%
OCT-2017	6 40%	3244 46%	6 40%	2986 42%	0 0%	65 1%	0 0%	4 0%	0 0%	4 0%	2 13%	245 3%	7 47%	3716 53%
NOV-2017	10 29%	3284 47%	9 26%	3028 43%	0 0%	65 1%	0 0%	5 0%	0 0%	4 0%	1 3%	265 4%	24 69%	3662 52%
DEC-2017	10 31%	3290 47%	10 31%	3036 43%	0 0%	64 1%	0 0%	5 0%	0 0%	4 0%	1 3%	272 4%	23 72%	3614 52%
JAN-2018	8 31%	3318 47%	7 27%	3074 43%	1 4%	61 1%	0 0%	5 0%	0 0%	4 0%	2 8%	292 4%	16 62%	3633 51%
FEB-2018	12 35%	3310 47%	11 32%	3068 44%	0 0%	61 1%	0 0%	5 0%	0 0%	4 0%	0 0%	297 4%	23 68%	3576 51%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





Monthly Report

**2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (continued)**

	emtricitabine			
	Initial		All	
JAN-2017	19	59%	3828	55%
FEB-2017	22	65%	3771	55%
MAR-2017	19	73%	3803	55%
APR-2017	19	59%	3791	55%
MAY-2017	25	74%	3795	54%
JUN-2017	24	80%	3797	54%
JUL-2017	12	63%	3770	54%
AUG-2017	24	80%	3767	53%
SEP-2017	19	66%	3740	53%
OCT-2017	8	53%	3733	53%
NOV-2017	25	71%	3695	53%
DEC-2017	22	69%	3668	52%
JAN-2018	18	69%	3710	52%
FEB-2018	22	65%	3669	52%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





**2.7 Number of Participants on Protease Inhibitor by INGREDIENT**

	(fos)amprenavir		atazanavir		darunavir		lopinavir		nelfinavir		ritonavir		saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2017	0 0%	9 0%	2 14%	1558 50%	12 86%	1312 42%	0 0%	247 8%	0 0%	3 0%	0 0%	1 0%	0 0%	12 0%
FEB-2017	0 0%	9 0%	3 19%	1518 49%	12 75%	1306 43%	1 6%	236 8%	0 0%	3 0%	0 0%	1 0%	0 0%	12 0%
MAR-2017	0 0%	8 0%	1 8%	1513 49%	11 92%	1329 43%	0 0%	232 8%	0 0%	2 0%	0 0%	1 0%	0 0%	12 0%
APR-2017	0 0%	8 0%	0 0%	1484 49%	5 71%	1318 43%	2 29%	231 8%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
MAY-2017	0 0%	9 0%	0 0%	1462 48%	14 100%	1350 44%	0 0%	227 7%	0 0%	3 0%	0 0%	1 0%	0 0%	11 0%
JUN-2017	0 0%	9 0%	2 18%	1453 48%	9 82%	1360 45%	0 0%	221 7%	0 0%	3 0%	0 0%	1 0%	0 0%	11 0%
JUL-2017	0 0%	9 0%	0 0%	1439 47%	6 100%	1360 45%	0 0%	218 7%	0 0%	3 0%	0 0%	1 0%	0 0%	11 0%
AUG-2017	0 0%	9 0%	1 5%	1417 47%	21 95%	1395 46%	0 0%	216 7%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
SEP-2017	0 0%	9 0%	0 0%	1388 46%	8 100%	1388 46%	0 0%	210 7%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
OCT-2017	0 0%	8 0%	0 0%	1365 46%	6 100%	1395 47%	0 0%	207 7%	0 0%	3 0%	0 0%	1 0%	0 0%	11 0%
NOV-2017	0 0%	8 0%	1 8%	1325 45%	10 83%	1390 47%	1 8%	206 7%	0 0%	3 0%	0 0%	1 0%	0 0%	10 0%
DEC-2017	0 0%	7 0%	1 7%	1295 45%	14 93%	1397 48%	0 0%	197 7%	0 0%	2 0%	0 0%	1 0%	0 0%	10 0%
JAN-2018	0 0%	8 0%	3 33%	1317 45%	6 67%	1418 48%	0 0%	195 7%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
FEB-2018	0 0%	6 0%	0 0%	1258 44%	15 100%	1416 49%	0 0%	189 7%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	tipranavir			
	Initial		All	
JAN-2017	0	0%	1	0%
FEB-2017	0	0%	1	0%
MAR-2017	0	0%	1	0%
APR-2017	0	0%	1	0%
MAY-2017	0	0%	1	0%
JUN-2017	0	0%	1	0%
JUL-2017	0	0%	1	0%
AUG-2017	0	0%	1	0%
SEP-2017	0	0%	1	0%
OCT-2017	0	0%	1	0%
NOV-2017	0	0%	1	0%
DEC-2017	0	0%	1	0%
JAN-2018	0	0%	1	0%
FEB-2018	0	0%	1	0%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





**2.8 Number of Participants on Non-Nucleosides by INGREDIENT**

	efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2017	4 80%	928 41%	0 0%	292 13%	1 20%	799 35%	0 0%	269 12%
FEB-2017	4 80%	907 40%	0 0%	280 12%	0 0%	791 35%	1 20%	266 12%
MAR-2017	1 50%	897 40%	0 0%	279 13%	0 0%	790 35%	1 50%	265 12%
APR-2017	4 44%	888 40%	0 0%	273 12%	1 11%	787 36%	4 44%	271 12%
MAY-2017	3 75%	877 40%	0 0%	274 12%	0 0%	783 35%	1 25%	279 13%
JUN-2017	3 100%	853 39%	0 0%	270 12%	0 0%	782 36%	0 0%	288 13%
JUL-2017	2 100%	838 39%	0 0%	264 12%	0 0%	779 36%	0 0%	283 13%
AUG-2017	1 100%	821 38%	0 0%	268 12%	0 0%	777 36%	0 0%	285 13%
SEP-2017	4 50%	808 38%	0 0%	264 12%	1 13%	774 36%	3 38%	296 14%
OCT-2017	2 100%	803 38%	0 0%	267 13%	0 0%	768 36%	0 0%	299 14%
NOV-2017	4 67%	800 38%	0 0%	269 13%	0 0%	767 36%	2 33%	300 14%
DEC-2017	3 75%	793 38%	0 0%	263 12%	0 0%	759 36%	1 25%	301 14%
JAN-2018	3 50%	776 37%	1 17%	264 13%	2 33%	757 36%	0 0%	302 14%
FEB-2018	3 75%	769 37%	0 0%	257 12%	0 0%	748 36%	1 25%	305 15%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





**2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT**

	dolutegravir		elvitegravir		maraviroc		raltegravir		enfuvirtide	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2017	13 81%	1518 53%	3 19%	587 20%	0 0%	52 2%	0 0%	756 26%	0 0%	1 0%
FEB-2017	14 78%	1560 54%	4 22%	588 20%	0 0%	48 2%	0 0%	732 25%	0 0%	1 0%
MAR-2017	13 87%	1620 55%	2 13%	601 20%	0 0%	49 2%	0 0%	732 25%	0 0%	1 0%
APR-2017	14 78%	1655 55%	4 22%	596 20%	0 0%	50 2%	0 0%	722 24%	0 0%	1 0%
MAY-2017	19 86%	1726 57%	3 14%	602 20%	0 0%	47 2%	0 0%	715 23%	0 0%	1 0%
JUN-2017	12 75%	1758 57%	3 19%	596 19%	0 0%	49 2%	1 6%	713 23%	0 0%	1 0%
JUL-2017	8 73%	1792 58%	3 27%	592 19%	0 0%	48 2%	0 0%	705 23%	0 0%	1 0%
AUG-2017	13 72%	1824 58%	4 22%	596 19%	0 0%	49 2%	1 6%	707 22%	0 0%	1 0%
SEP-2017	10 71%	1834 58%	4 29%	600 19%	0 0%	50 2%	0 0%	700 22%	0 0%	1 0%
OCT-2017	9 90%	1882 59%	1 10%	608 19%	0 0%	48 1%	0 0%	708 22%	0 0%	0 0%
NOV-2017	15 68%	1942 60%	5 23%	612 19%	0 0%	49 2%	2 9%	701 21%	0 0%	0 0%
DEC-2017	11 65%	1961 60%	6 35%	605 18%	0 0%	48 1%	0 0%	689 21%	0 0%	0 0%
JAN-2018	8 47%	2006 60%	8 47%	632 19%	0 0%	46 1%	1 6%	688 21%	0 0%	0 0%
FEB-2018	14 70%	2018 60%	5 25%	638 19%	0 0%	45 1%	1 5%	675 20%	0 0%	0 0%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





### 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2017	2155	30.01	1793	24.97	2135	29.73	139	1.94	63	0.88	897	12.49
FEB-2017	2125	29.79	1772	24.84	2165	30.35	133	1.86	55	0.77	884	12.39
MAR-2017	2133	29.68	1754	24.41	2223	30.94	134	1.86	58	0.81	884	12.30
APR-2017	2109	29.38	1744	24.30	2260	31.49	133	1.85	59	0.82	873	12.16
MAY-2017	2108	29.18	1737	24.04	2308	31.95	132	1.83	59	0.82	880	12.18
JUN-2017	2115	29.19	1719	23.72	2349	32.42	132	1.82	59	0.81	872	12.03
JUL-2017	2102	29.03	1694	23.39	2386	32.95	130	1.80	62	0.86	868	11.99
AUG-2017	2094	28.82	1687	23.22	2408	33.14	130	1.79	61	0.84	886	12.19
SEP-2017	2074	28.71	1676	23.20	2428	33.61	127	1.76	57	0.79	861	11.92
OCT-2017	2051	28.29	1675	23.11	2479	34.20	124	1.71	57	0.79	863	11.91
NOV-2017	2005	27.67	1668	23.02	2524	34.83	119	1.64	56	0.77	874	12.06
DEC-2017	1999	27.63	1661	22.96	2536	35.06	115	1.59	56	0.77	867	11.99
JAN-2018	2009	27.56	1643	22.54	2596	35.61	117	1.60	55	0.75	870	11.93
FEB-2018	1964	27.14	1628	22.50	2605	36.00	116	1.60	58	0.80	866	11.97

**Definitions:**

n is number of participants on the specified regimen class in the specified month  
 % is ratio of n and total number of participants on ART in the specified month





**2.11 Baseline CD4 for Antiretroviral First Starts**

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2017	21	3	2	3	6	6	390
FEB-2017	24	5	3	1	3	10	425
MAR-2017	19	5	3	5	2	2	220
APR-2017	20	1	2	6	5	5	350
MAY-2017	22	2	0	3	9	8	405
JUN-2017	24	6	2	5	3	7	230
JUL-2017	14	2	2	2	1	5	340
AUG-2017	25	4	0	4	3	12	510
SEP-2017	16	1	2	3	3	5	440
OCT-2017	7	2	0	0	1	3	545
NOV-2017	20	2	2	6	3	7	385
DEC-2017	19	2	2	4	4	6	405
JAN-2018	10	1	1	0	3	4	490
FEB-2018	24	2	1	2	6	12	510

**Definitions:**

**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)

**Baseline CD4** is defined as most recent CD4 test before ARV start





**2.12 DTP Participants with PVL Measurement within previous five years, and never on ART**

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2017	11582	3396
FEB-2017	11607	3403
MAR-2017	11658	3452
APR-2017	11684	3467
MAY-2017	11725	3492
JUN-2017	11754	3508
JUL-2017	11787	3539
AUG-2017	11822	3565
SEP-2017	11849	3590
OCT-2017	11907	3642
NOV-2017	11920	3642
DEC-2017	11948	3647
JAN-2018	12009	3692
FEB-2018	12047	3712

**Definitions:**

**Patients with PVL test** are defined as having at least one PVL test within previous five years, and not reported deceased/moved

**Never on ART** are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants  
February 2018

N = 7237

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participants

February 2018

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



KELOWNA BY POSTAL CODE







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

February 2018

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

February 2018

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

February 2018

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

February 2018

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





**4.1 Distribution of Participants in BC-CfE Registries by Age and Gender  
INTERIOR Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>	<b>35</b>	<b>48</b>	<b>24</b>
KOOTENAY BOUNDARY	0-19	*	*	0
	20-34	*	*	0
	35-49	*	*	9
	50+	*	*	41
<b>Total HSDA:</b>	<b>72</b>	<b>95</b>	<b>50</b>	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HSDA:</b>	<b>348</b>	<b>466</b>	<b>260</b>	
THOMPSON/CARIBOO/ SHUSWAP	0-19	*	*	0
	20-34	*	*	17
	35-49	*	*	42
	50+	*	*	76
<b>Total HSDA:</b>	<b>177</b>	<b>237</b>	<b>135</b>	
<b>Total HA:</b>		<b>632</b>	<b>846</b>	<b>469</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HA:</b>		<b>632</b>	<b>846</b>	<b>469</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	494	671	375
Female	138	175	94

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	469	54	580	35

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration  
INTERIOR Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	18	*
	5 years or more	6	*
	<5 years	11	*
	<b>Total HSDA:</b>	<b>35</b>	<b>24</b>
KOOTENAY BOUNDARY	10 years or more	40	27
	5 years or more	20	16
	<5 years	12	7
	<b>Total HSDA:</b>	<b>72</b>	<b>50</b>
OKANAGAN	10 years or more	200	138
	5 years or more	75	63
	<5 years	73	59
	<b>Total HSDA:</b>	<b>348</b>	<b>260</b>
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	91	61
	5 years or more	38	34
	<5 years	48	40
	<b>Total HSDA:</b>	<b>177</b>	<b>135</b>
<b>Total HA:</b>		<b>632</b>	<b>469</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	349	237
	5 years or more	139	117
	<5 years	144	115
<b>Total HA:</b>		<b>632</b>	<b>469</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





### 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	38	55	13	22
KOOTENAY BOUNDARY	65	116	23	43
OKANAGAN	204	764	62	267
THOMPSON/CARIBOO/SHUSWAP	127	462	35	120
<b>Total:</b>	<b>434</b>	<b>1397</b>	<b>133</b>	<b>452</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
<b>Total:</b>	<b>82</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





#### 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	6	6	5
	20-34	27	28	18
	35-49	104	115	67
	50+	199	268	154
	<b>Total HSDA:</b>	<b>336</b>	<b>417</b>	<b>244</b>
FRASER NORTH	0-19	12	12	*
	20-34	106	107	*
	35-49	348	387	*
	50+	516	814	*
	<b>Total HSDA:</b>	<b>982</b>	<b>1320</b>	<b>763</b>
FRASER SOUTH	0-19	8	8	5
	20-34	101	103	75
	35-49	358	408	288
	50+	478	705	402
	<b>Total HSDA:</b>	<b>945</b>	<b>1224</b>	<b>770</b>
<b>Total HA:</b>		<b>2263</b>	<b>2961</b>	<b>1777</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	26	26	12
	20-34	234	238	171
	35-49	810	910	624
	50+	1193	1787	970
<b>Total HA:</b>		<b>2263</b>	<b>2961</b>	<b>1777</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1723	2282	1385
Female	540	679	392

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	1777	51	620	35

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration  
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	174	121
	5 years or more	95	73
	<5 years	67	50
	<b>Total HSDA:</b>	<b>336</b>	<b>244</b>
FRASER NORTH	10 years or more	496	357
	5 years or more	251	195
	<5 years	235	211
	<b>Total HSDA:</b>	<b>982</b>	<b>763</b>
FRASER SOUTH	10 years or more	467	370
	5 years or more	243	194
	<5 years	235	206
	<b>Total HSDA:</b>	<b>945</b>	<b>770</b>
<b>Total HA:</b>		<b>2263</b>	<b>1777</b>

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	1137	848
5 years or more	589	462
<5 years	537	467
<b>Total HA:</b>	<b>2263</b>	<b>1777</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





#### 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries FRASER Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	133	451	37	71
FRASER NORTH	240	1514	54	249
FRASER SOUTH	208	1267	45	356
<b>Total:</b>	<b>581</b>	<b>3232</b>	<b>136</b>	<b>676</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	185
FRASER NORTH	660
FRASER SOUTH	521
<b>Total:</b>	<b>1366</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender  
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	0
	20-34	*	*	22
	35-49	*	*	66
	50+	*	*	187
	<b>Total HSDA:</b>		<b>320</b>	<b>462</b>
RICHMOND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>164</b>	<b>210</b>
VANCOUVER	0-19	40	43	*
	20-34	442	453	*
	35-49	1488	1685	*
	50+	2661	4473	*
	<b>Total HSDA:</b>	<b>4631</b>	<b>6654</b>	<b>3458</b>
<b>Total HA:</b>		<b>5115</b>	<b>7326</b>	<b>3858</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	44	47	5
	20-34	491	503	362
	35-49	1612	1825	1181
	50+	2968	4951	2310
<b>Total HA:</b>		<b>5115</b>	<b>7326</b>	<b>3858</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
	2	2	0
Male	4492	6431	3404
Female	621	893	454

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	3858	52	630	35

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration  
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	166	138
	5 years or more	79	67
	<5 years	75	70
	<b>Total HSDA:</b>	<b>320</b>	<b>275</b>
RICHMOND	10 years or more	82	60
	5 years or more	43	33
	<5 years	39	32
	<b>Total HSDA:</b>	<b>164</b>	<b>125</b>
VANCOUVER	10 years or more	2520	1808
	5 years or more	1214	920
	<5 years	897	730
	Never on ART	0	0
	<b>Total HSDA:</b>	<b>4631</b>	<b>3458</b>
<b>Total HA:</b>	<b>5115</b>	<b>3858</b>	

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	2768	2006
5 years or more	1336	1020
<5 years	1011	832
Never on ART	0	0
<b>Total HA:</b>	<b>5115</b>	<b>3858</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	157	418	55	127
RICHMOND	42	276	13	92
VANCOUVER	566	10435	208	5372
<b>Total:</b>	<b>765</b>	<b>11129</b>	<b>276</b>	<b>5591</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
<b>Total:</b>	<b>166</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender  
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>309</b>	<b>430</b>
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>119</b>	<b>157</b>
SOUTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>703</b>	<b>984</b>
<b>Total HA:</b>		<b>1131</b>	<b>1571</b>	<b>875</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	9	9	*
	20-34	99	105	*
	35-49	315	360	*
	50+	708	1097	*
<b>Total HA:</b>		<b>1131</b>	<b>1571</b>	<b>875</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	925	1286	724
Female	206	285	151

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	875	53	520	35

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	146	118
	5 years or more	75	62
	<5 years	88	72
	<b>Total HSDA:</b>	<b>309</b>	<b>252</b>
NORTH VANCOUVER ISLAND	10 years or more	63	52
	5 years or more	30	23
	<5 years	26	19
	<b>Total HSDA:</b>	<b>119</b>	<b>94</b>
SOUTH VANCOUVER ISLAND	10 years or more	382	267
	5 years or more	161	131
	<5 years	160	131
	<b>Total HSDA:</b>	<b>703</b>	<b>529</b>
<b>Total HA:</b>		<b>1131</b>	<b>875</b>

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	591	437
5 years or more	266	216
<5 years	274	222
<b>Total HA:</b>	<b>1131</b>	<b>875</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	185	817	78	204
NORTH VANCOUVER ISLAND	124	253	40	73
SOUTH VANCOUVER ISLAND	199	1666	43	543
<b>Total:</b>	<b>508</b>	<b>2736</b>	<b>161</b>	<b>820</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	47
NORTH VANCOUVER ISLAND	32
SOUTH VANCOUVER ISLAND	107
<b>Total:</b>	<b>186</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Gender  
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>40</b>	<b>48</b>
NORTH WEST	0-19	*	*	0
	20-34	*	*	6
	35-49	*	*	16
	50+	*	*	28
	<b>Total HSDA:</b>		<b>68</b>	<b>104</b>
NORTHERN INTERIOR	0-19	6	6	*
	20-34	25	28	*
	35-49	77	94	*
	50+	87	138	*
	<b>Total HSDA:</b>		<b>195</b>	<b>266</b>
<b>Total HA:</b>		<b>303</b>	<b>418</b>	<b>219</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	9	9	*
	20-34	37	41	*
	35-49	113	149	*
	50+	144	219	*
<b>Total HA:</b>		<b>303</b>	<b>418</b>	<b>219</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	186	261	141
Female	117	157	78

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	219	50	540	35

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration  
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	17	7
	5 years or more	14	9
	<5 years	9	7
	<b>Total HSDA:</b>	<b>40</b>	<b>23</b>
NORTH WEST	10 years or more	23	13
	5 years or more	31	27
	<5 years	14	10
	<b>Total HSDA:</b>	<b>68</b>	<b>50</b>
NORTHERN INTERIOR	10 years or more	64	41
	5 years or more	70	60
	<5 years	61	45
	<b>Total HSDA:</b>	<b>195</b>	<b>146</b>
<b>Total HA:</b>		<b>303</b>	<b>219</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	104	61
	5 years or more	115	96
	<5 years	84	62
<b>Total HA:</b>		<b>303</b>	<b>219</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	37	61	9	10
NORTH WEST	68	151	17	28
NORTHERN INTERIOR	102	426	17	183
<b>Total:</b>	<b>207</b>	<b>638</b>	<b>43</b>	<b>221</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	7
NORTH WEST	14
NORTHERN INTERIOR	26
<b>Total:</b>	<b>47</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender**

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	*	10	*
	KOOTENAY BOUNDARY	*	7	*
	OKANAGAN	*	33	*
	THOMPSON/CARIBOO/SHUSWAP	*	40	*
	<b>Total HA:</b>	<b>51</b>	<b>90</b>	<b>37</b>
FRASER	FRASER EAST	32	41	22
	FRASER NORTH	50	83	43
	FRASER SOUTH	70	101	53
	<b>Total HA:</b>	<b>152</b>	<b>225</b>	<b>118</b>
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	26	47	25
	RICHMOND	11	16	9
	VANCOUVER	512	837	416
	<b>Total HA:</b>	<b>549</b>	<b>900</b>	<b>450</b>
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	51	77	41
	NORTH VANCOUVER ISLAND	17	26	13
	SOUTH VANCOUVER ISLAND	35	75	28
	<b>Total HA:</b>	<b>103</b>	<b>178</b>	<b>82</b>
NORTHERN	NORTH EAST	9	11	7
	NORTH WEST	31	58	26
	NORTHERN INTERIOR	72	105	61
	<b>Total HA:</b>	<b>112</b>	<b>174</b>	<b>94</b>
<b>Total:</b>		<b>967</b>	<b>1567</b>	<b>781</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	599	1001	481
Female	368	566	300

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total:</b>	781	50	490	35

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





## 5.1 Drug Names and Definitions

**Abacavir (Ziagen, ABC):** a NUCLEOSIDE ANALOG from ViiV Healthcare.

**Active:** persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

**Amphotericin B (Fungilin):** a drug used for treatment of candidiasis and other fungal infections.

**Amprenavir (Agenerase, APV):** a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

**Antiretroviral (ARV):** a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

**Atazanavir (Reyataz, ATV):** a PROTEASE INHIBITOR from Bristol-Myers Squibb.

**Atovaquone (Mepron):** a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

**Atripla (ATP):** the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

**Azithromycin (Zithromax):** an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

**Boosted PI:** a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

**CD4 Cell Count:** the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

**Chemokine Receptor Inhibitor:** a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

**Clarithromycin (Biaxin):** an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

**Cobicstat:** a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicstat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

**Combination Therapy:** initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

**Combivir (CBV):** the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

**Complera (CPL):** the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

**Darunavir (Prezista, DRV):** a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

**Deceased:** persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

**Delavirdine (Rescriptor, DLV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from ViiV Healthcare.





**Descovy (DSC):** the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

**Didanosine (Videx, DDI):** a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

**Dolutegravir (Tivicay, DTG):** an INTEGRASE INHIBITOR from ViiV Healthcare.

**Efavirenz (Sustiva, Auro efavirenz, EFV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

**Elvitegravir (EGV):** an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

**Emtricitabine (FTC):** a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

**Enfuvirtide (Fuzeon, T20):** a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

**Entry Inhibitor:** a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

**Etravirine (Intence, ETV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

**Ethambutol (Myambutol):** an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

**First started program:** a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

**Fosamprenavir (Telzir, fAPV):** a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

**Fusion Inhibitor:** a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

**Genvoya (GNV):** the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

**Granulocyte Colony Stimulating Factor (GCSF, Neupogen):** a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

**Health Authority:** refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

**Inactive:** persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

**Indinavir (Crixivan, IDV):** a PROTEASE INHIBITOR from Merck.

**Integrase Inhibitor:** a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

**Kivexa (KIV):** the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

**Lamivudine (3TC):** a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

**Lopinavir (Kaletra, LPV/r):** a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.





**Maraviroc (Celsentri, MVC):** a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

**Median (MED) age:** median age of participants in the HIV/AIDS Drug Treatment program in that time period.

**MDRT:** see MULTIPLE DRUG RESCUE THERAPY

**Moved out of BC:** a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

**Moxifloxacin:** a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

**Multiple Drug Rescue Therapy (MDRT or Mega-HAART):** the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

**Nelfinavir (Viracept, NFV):** a PROTEASE INHIBITOR from ViiV Healthcare.

**Net change:** the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

**Nevirapine (Viramune, NVP):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

**NNRTI:** see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

**NNRTI / no PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

**Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI):** a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

**NRTI:** see NUCLEOSIDE ANALOG.

**Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI):** a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

**Nucleotide Analog:** ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

**Octreotide Acetate (Sandostatin):** a drug used to treat chronic refractory diarrhea.

**Odefsey (ODF):** the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

**One or more PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

**Other:** an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

**Paromomycin (Humatin):** an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.





**Pentamidine:** an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

**PI:** see PROTEASE INHIBITOR.

**Prezcobix (PZC):** the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

**Prodrug:** a compound that is converted within the body into the active form that has medical effects.

**Protease Inhibitor:** a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

**Raltegravir (RGV, Isentress):** an INTEGRASE INHIBITOR from Merck.

**Restarted/ changed therapy (Tx):** a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

**Rifabutin (Mycobutin):** an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

**Rilpivirine (Edurant, RPV):** a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

**Ritonavir (Norvir, RTV):** a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

**Saquinavir (Invirase, SQV):** a PROTEASE INHIBITOR from Hoffman-La Roche.

**Stavudine (Zerit, d4T):** a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

**Stopped all therapies (Tx):** a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

**Stribild (STR):** the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

**Tenofovir alafenamide (Tenofovir AF, TAF):** a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

**Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF):** a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

**Tipranavir (Aptivus, TPV):** a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

**Triple Therapy:** the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

**Triumeq (TRQ):** the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

**Trizivir (TRZ):** the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

**Truvada (TRU):** the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.





**Valganciclovir:** an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

**Viral Load:** the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

**Zidovudine (Retrovir, AZT):** a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

